沃替西汀与SSRIs在老年重性抑郁症中的耐受性与疗效:VESPA研究方案
VESPA研究是一项由意大利药品管理局资助的实用型、多中心、开放标签、平行组、优效性随机试验,计划纳入358例老年重性抑郁症患者,比较沃替西汀与SSRIs(作为一组)的耐受性。主要结局为随访6个月时因不良事件退出治疗的比例,同时评估抑郁症状、副作用、生活质量、认知和共病情况。
要点
- 沃替西汀可能对老年抑郁症患者耐受性更优,但需随机试验验证。
- 主要结局为6个月因不良事件退出率,样本量358例(每组179例)。
- 采用MADRS、ASEC、EQ-5D、SBT和CACI等量表评估多维结局。
核心结论
- 该研究旨在评估沃替西汀相比SSRIs在老年抑郁症患者中的耐受性,主要结局为6个月因不良事件退出治疗的比例。
研究设计与样本
- 实用型、多中心、开放标签、平行组、优效性随机试验,由意大利药品管理局资助。
- 参与者将在基线及随访1、3、6个月时接受评估,结局评估者和统计师对治疗分配设盲。
关键数值与推荐
- 主要结局:随访6个月时因不良事件退出治疗的比例。
- 评估量表包括MADRS、ASEC、EQ-5D、SBT和CACI。
临床怎么用
- 若沃替西汀耐受性优于SSRIs,可为老年抑郁症患者提供更安全的治疗选择。
局限性
- 开放标签设计可能引入偏倚,SSRIs作为一组分析可能掩盖组间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Depression is a highly prevalent condition in the elderly, with a vast impact on quality of life, life expectancy, and medical outcomes. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed agents in this condition and, although generally safe, tolerability issues cannot be overlooked. Vortioxetine is an antidepressant with a novel mechanism of action. Based on studies to date, it may have a promising tolerability profile in the elderly, as it does not adversely affect psychomotor or cognitive performance and does not alter cardiovascular and endocrine parameters. The present study aims to assess the tolerability profile of vortioxetine in comparison with the SSRIs considered as a single group in elderly participants with depression. The rate of participants withdrawing from treatment due to adverse events after 6 months of follow up will be the primary outcome. METHODS AND ANALYSIS: This is a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial funded by the Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco). Thirteen Italian Community Psychiatric Services will consecutively enrol elderly participants suffering from an episode of major depression over a period of 12 months. Participants will be assessed at baseline and after 1, 3 and 6 months of follow up. At each time point, the following validated rating scales will be administered: Montgomery-Åsberg Depression Rating Scale (MADRS), Antidepressant Side-Effect Checklist (ASEC), EuroQual 5 Dimensions (EQ-5D), Short Blessed Test (SBT), and Charlson Age-Comorbidity Index (CACI). Outcome assessors and the statistician will be masked to treatment allocation. A total of 358 participants (179 in each group) will be enrolled. ETHICS AND DISSEMINATION: This study will fully adhere to the ICH E6 Guideline for Good Clinical Practice. Participants' data will be managed and safeguarded according to the European Data Protection Regulation 2016/679. An external Ethical Advisory Board will help guarantee high ethical standards. TRIAL REGISTRATION: Clinicaltrials.gov: NCT03779789 , Registered on 19 December 2018. Submitted on 19 December. EudraCT number: 2018-001444-66. TRIAL STATUS: Protocol version 1.5; 09/06/2018. Recruitment started In February 2019 and it is ongoing. It is expected to end approximately on 30 September 2021.
引用
- Ostuzzi G, Gastaldon C, Barbato A, et al. Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial. Trials. 2020. PMID: 32746941. doi:10.1186/s13063-020-04460-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。